Taken together, our results suggest that, due to the antibody arm, treatment of the CLL patient-derived PBMCs with scFvB1IL15 enhanced the effects of IL15 on the CD56-positive subpopulation, thus potentiating the effects of free IL15 and resulting in the specific stimulation of NK cells. This evidence concerns the gene NCAM1 and B-cell chronic lymphocytic leukemia.